Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislav Drápela

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 10, 2022
High-Throughput, Parallel Flow Cytometry Screening of Hundreds of Cell Surface Antigens Using Fluorescent BarcodingStanislav Drápela, Radek Fedr, Ondřej Vacek, et al.
Frontiers in Molecular Biosciences|April 9, 2020
ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy ResistanceStanislav Drápela, Jan Bouchal, Mohit Kumar Jolly, et al.
Cell Death & Disease|August 17, 2023
Circulating tumor cell-derived preclinical models: current status and future perspectivesZuzana Kahounová, Markéta Pícková, Stanislav Drápela, et al.
European Journal of Medicinal Chemistry|February 26, 2021
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine coreVáclav Němec, Lukáš Maier, Benedict-Tilman Berger, et al.
The Journal of Organic Chemistry|March 8, 2017
Diastereoselective Flexible Synthesis of Carbocyclic C-NucleosidesLukáš Maier, Prashant Khirsariya, Ondřej Hylse, et al.
British Journal of Cancer|May 18, 2026
Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancerZuzana Kahounová, Markéta Hrušková, Stanislav Drápela, et al.
Molecular Oncology|June 25, 2020
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastropheStanislav Drápela, Prashant Khirsariya, Wytske M van Weerden, et al.
Angewandte Chemie (International Ed. in English)|December 21, 2018
Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog PathwayVáclav Němec, Michaela Hylsová, Lukáš Maier, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2024
Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cellsStanislav Drápela, Barbora Kvokačková, Eva Slabáková, et al.
Molecular Cancer Therapeutics|June 17, 2017
Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylationPounami Samadder, Tereza Suchánková, Ondřej Hylse, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|September 10, 2022
High-Throughput, Parallel Flow Cytometry Screening of Hundreds of Cell Surface Antigens Using Fluorescent BarcodingStanislav Drápela, Radek Fedr, Ondřej Vacek, et al.
Frontiers in Molecular Biosciences|April 9, 2020
ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy ResistanceStanislav Drápela, Jan Bouchal, Mohit Kumar Jolly, et al.
Cell Death & Disease|August 17, 2023
Circulating tumor cell-derived preclinical models: current status and future perspectivesZuzana Kahounová, Markéta Pícková, Stanislav Drápela, et al.
European Journal of Medicinal Chemistry|February 26, 2021
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine coreVáclav Němec, Lukáš Maier, Benedict-Tilman Berger, et al.
The Journal of Organic Chemistry|March 8, 2017
Diastereoselective Flexible Synthesis of Carbocyclic C-NucleosidesLukáš Maier, Prashant Khirsariya, Ondřej Hylse, et al.
British Journal of Cancer|May 18, 2026
Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancerZuzana Kahounová, Markéta Hrušková, Stanislav Drápela, et al.
Molecular Oncology|June 25, 2020
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastropheStanislav Drápela, Prashant Khirsariya, Wytske M van Weerden, et al.
Angewandte Chemie (International Ed. in English)|December 21, 2018
Furo[3,2-b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog PathwayVáclav Němec, Michaela Hylsová, Lukáš Maier, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2024
Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cellsStanislav Drápela, Barbora Kvokačková, Eva Slabáková, et al.
Molecular Cancer Therapeutics|June 17, 2017
Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylationPounami Samadder, Tereza Suchánková, Ondřej Hylse, et al.
Pageof 2